China’s weight-loss drug market has officially entered the oral era. China’s National Medical Products Administration announced on Nov. 12 that it approved orforglipron calcium tablets (brand name Muyouda), a Class 1 innovative drug filed by Eli Lilly, making it the first oral GLP-1 receptor agonist cleared in China for adult weight management. It also means the multibillion-dollar obesity market that injectable pens have dominated for the past several years is shifting its competitive axis from the needle tip to the tongue.

Under the approval, Muyouda is indicated for long-term weight management in adults with an initial body mass index of 30 kg/m² or higher who are obese, or adults with a BMI of 27 to 30 kg/m² who have at least one weight-related comorbidity such as hypertension, dyslipidemia, high blood sugar, obstructive sleep apnea or cardiovascular disease, in addition to diet control and increased exercise. Eli Lilly’s China unit said China is one of the first markets globally to approve the drug, and that its indication for type 2 diabetes in adults is still under review.

Small-molecule design breaks the peptide oral barrier

What sets Muyouda apart from existing oral products is its molecular pathway. GLP-1 drugs have mostly been peptide molecules that are easily broken down by stomach acid and poorly absorbed in the gut when taken orally, so the mainstream route of administration has long remained subcutaneous injection. Eli Lilly switched to a non-peptide small-molecule design that lets the drug be absorbed through the digestive tract like an ordinary oral chemical medicine; it is taken as one tablet daily at any time of day, without food or water restrictions and without the need for refrigeration.

The core data supporting approval came from the Phase 3 ATTAIN-1 clinical trial. Patients in the highest 36 mg daily dose group lost an average of 12.4% of body weight after 72 consecutive weeks of treatment. Eli Lilly added that patients in that group lost an average of about 12.4 kilograms, nearly 40% lost more than 15% of body weight, visceral fat fell by more than 30% and waist circumference shrank by as much as about 11 centimeters. Eli Lilly’s China medical team said the drug has completed eight Phase 3 studies worldwide in obesity and type 2 diabetes enrolling more than 10,000 people, with Chinese patients participating in six global multicenter studies.

Mu Yiming, director of the endocrinology department at Chinese People’s Liberation Army General Hospital, said the drug showed good weight-loss results among overweight and obese patients in China and produced clinically meaningful improvements in risk factors including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure.

Two giants vie as oral forms become the new battleground

The weight-loss drug rivalry between Eli Lilly and Novo Nordisk is extending from injectables to oral formulations. Novo Nordisk has taken the “oralized peptide” route, using SNAC technology to overcome the stomach-acid degradation barrier; its weight-loss version of oral semaglutide tablets is already on the market in the United States, and its application in China for long-term weight management was accepted in August this year, putting its review progress slightly behind Eli Lilly’s. The drug, however, must be taken on an empty stomach, with a 30-minute wait before eating or drinking, which relatively limits adherence.

By revenue scale, Eli Lilly remains in the lead. In the first three quarters of 2026, the tirzepatide franchise generated combined sales of about $43.768 billion, roughly 65% of Eli Lilly’s total revenue, of which the China market contributed $2.582 billion, up 75% year on year. Novo Nordisk’s four semaglutide products totaled about $26.85 billion over the same period, but it holds the upper hand for now in the oral weight-loss subsegment.

Notably, the U.S. Food and Drug Administration issued a notice on Nov. 9 saying that use of GLP-1 receptor agonist drugs may increase the risk of a rare eye condition that can cause permanent vision loss, and required the relevant medicines to add a warning to their labeling, covering semaglutide, liraglutide and tirzepatide, among others. Novo Nordisk said it will continue to monitor drug safety and remains confident in the benefit-risk profile of its medicines; Eli Lilly said it is evaluating the update and noted that the notice did not list specific cases involving Eli Lilly drugs.

Chinese drugmakers chase with differentiated strategies

As multinational drugmakers secure the first approvals, the filing pace of Chinese companies is also compressing rivals’ first-mover window. VCT220 from Chinese drugmaker Vantai Medicine was the first oral small-molecule new drug application submitted, in July this year; Hengrui Medicine’s HRS-7535 was accepted in September; and Huadong Medicine’s Conveglipron is in the final stretch of Phase 3. Industry analysts say that, facing the first-mover positions of Eli Lilly and Novo Nordisk, the breakthrough point for Chinese manufacturers lies not in head-on competition on the same mechanism but in differentiated indications and combination therapies.

Pfizer offers another reference point. Its in-house oral small molecules Lotiglipron and Danuglipron were successively terminated over safety issues, leaving it temporarily absent from the oral segment; it instead licensed a next-generation cAMP-biased GLP-1 receptor agonist, ecnoglutide, which won approval in China in April this year for both weight loss and diabetes and has begun sales.

Market size and pricing in focus

Market institutions hold high expectations for Muyouda’s commercial prospects. Jefferies analyst Akash Tewari estimates the drug’s global peak annual sales could exceed $25 billion, while other institutions forecast first-year sales of about $1 billion and a long-term peak of between $25 billion and $43 billion. For comparison, Goldman Sachs previously estimated the overall global oral weight-loss drug market at about $22 billion in 2030.

On pricing, Eli Lilly’s China unit said it will reference pricing at formal medical institutions after commercial launch. The U.S. self-pay market offers a reference: the lowest dose is priced at $149 per month, the regular monthly cost for patients is about $349, and refill discounts can bring it as low as $299.

On the supply chain, Eli Lilly announced in March this year a cumulative investment of $3 billion over the next decade to expand production capacity in China and build a local manufacturing and supply system for oral solid formulations. Eli Lilly Executive Vice President Patrik Jonsson confirmed that there is no supply-shortage constraint in the China market.

Impact analysis

The most direct significance of the arrival of an oral formulation is that it lowers the barrier to treatment. Although injectables have already pushed weight loss to around 15%, they have never overcome three patient hurdles: fear of needles, inconvenience and dependence on cold chain; oral small molecules are expected to capture needle-averse patients, maintenance-phase patients and new users with low adherence.

Oral forms, however, are not a substitute for injections. Eli Lilly’s choice to run “one shot, one pill” in parallel rather than replace injections with oral drugs rests on exactly this logic. For investors, the real contest is not review speed but what happens after approval: whoever can embed “one pill a day” into a closed loop of follow-up, refills and behavior management will win the long-term repeat-purchase market. With oral and injectable lines running in parallel, competition in China’s weight-loss market will become more diverse, and the pricing, channel and physician-education capabilities of Chinese and multinational drugmakers will be the focus of the next stage.